Myeloma Treatment Trends

FDA Approves Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has approved the use of Darzalex® (daratumumab) in combination with Pomalyst® (pomalidomide) and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including Revlimid® (lenalidomide) and a proteasome inhibitor. Learn more from this ASCO POST. ​

Save the Date: Myeloma Updates 2017: Best of ASCO/EHA/IMWG Webinar - July 13th, 2017 

On Thursday, July 13th, 2017 at 4:00 PM PT / 7:00 PM ET, Dr. Brian Durie will explain the new and exciting current trends in myeloma treatment and research during a Myeloma Updates 2017 webinar. This webinar will feature updates from the three major medical meetings held in June 2017 – the American Society of Clinical Oncology (ASCO), the European Hematology Association (EHA), and the International Myeloma Working Group Summit (IMWG). Register for FREE now for this webinar that includes a Q&A session

 

Read the Latest Issue of Making Miracles and Celebrate Your Contributions to the Myeloma Community

Welcome to our latest edition of Making Miracles! It’s a joy and a privilege to create this magazine that celebrates all you do in support of the IMF. In 2016, more than 50 member-led events raised funds and awareness for our cause: members sampled rare wines, crossed marathon finish lines, paddled huge distances, shared laughs at comedy shows, and even grew facial hair to raise myeloma awareness. Read all about members like you and their efforts to support the myeloma community. Gain ideas of what you can do to inspire others in the years to come!

 

View the IMF Nurse Leadership Board (NLB) Satellite Symposium Videos and Slides

The IMF Nurse Leadership Board (NLB) satellite symposium at the Oncology Nursing Society (ONS) annual conference was attended by 835 nurses. Held on May 4th, 2017 in Denver, Colorado, the successful event featured a presentation on “Case Studies in Multiple Myeloma: Best Practices in Patient Care and Symptom Management.” View videos and slides of all seven case studies: Case Study 1: Multiple Myeloma Background; Case Studies 2 & 3: Bone Health and Renal Health; and Case Studies 4, 5, 6, & 7: Relapsed Myeloma, Treatment for Relapsed MM, and Drugs in Development.

Calling All Researchers: Submit Your Grant Applications!

The Brian D. Novis Research Grants honor the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The grants are awarded to researchers in the field of multiple myeloma and related disorders including SMM (smoldering multiple myeloma), MGUS (monoclonal gammopathy of undetermined significance), and immunoglobulin-derived amyloidosis. The 2018 grants will fund senior research projects with $80,000 and junior research projects with $50,000. Tuesday, August1st, 2017, is the deadline for applications.

 

What it means if ß2-microglobulin is increased, but all other testing shows remission?

In this week's video, Dr. Brian Durie explains why serum ß2-microglobulin may increase in some myeloma patients, but does not indicate relapse.

 

 


We Thank Our Sponsors: Amgen, Celgene Corporation, Genentech, Janssen Pharmaceuticals, and Takeda Oncology